Division of Cardiology, Hennepin County Medical Center and Minneapolis Heart Institute, Abbott Northwestern Hospital, Minn.
Department of Emergency Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis.
Am J Med. 2017 Sep;130(9):1076-1083.e1. doi: 10.1016/j.amjmed.2017.02.032. Epub 2017 Mar 24.
This study examined the performance of single high-sensitivity cardiac troponin I (hs-cTnI) measurement strategies to rule out acute myocardial infarction.
This was a prospective, observational study of consecutive patients presenting to the emergency department (n = 1631) in whom cTnI measurements were obtained using an investigational hs-cTnI assay. The goals of the study were to determine 1) negative predictive value (NPV) and sensitivity for the diagnosis of acute myocardial infarction, type 1 myocardial infarction, and type 2 myocardial infarction; and 2) safety outcome of acute myocardial infarction or cardiac death at 30 days using hs-cTnI less than the limit of detection (LoD) (<1.9 ng/L) or the High-STEACS threshold (<5 ng/L) alone and in combination with normal electrocardiogram (ECG).
Acute myocardial infarction occurred in 170 patients (10.4%), including 68 (4.2%) type 1 myocardial infarction and 102 (6.3%) type 2 myocardial infarction. For hs-cTnI<LoD (27%), the NPV and sensitivity for acute myocardial infarction were 99.6% (95% confidence interval 98.9%-100%) and 98.8 (97.2%-100%). For hs-cTnI<5 ng/L (50%), the NPV and sensitivity for acute myocardial infarction were 98.9% (98.2%-99.6%) and 94.7% (91.3%-98.1%). In combination with a normal ECG, 1) hs-cTnI<LoD had an NPV of 99.6% (98.9%-100%) and sensitivity of 99.4% (98.3%-100%); and 2) hs-cTnI<5 ng/L had an NPV of 99.5% (98.8%-100%) and sensitivity of 98.8% (97.2%-100%). The NPV and sensitivity for the safety outcome were excellent for hs-cTnI<LoD alone or in combination with a normal ECG, and for hs-cTnI<5 ng/L in combination with a normal ECG.
Strategies using a single hs-cTnI alone or in combination with a normal ECG allow the immediate identification of patients unlikely to have acute myocardial infarction and who are at very low risk for adverse events at 30 days.
本研究旨在评估单次高敏肌钙蛋白 I(hs-cTnI)检测策略用于排除急性心肌梗死的性能。
这是一项前瞻性、观察性研究,连续纳入了 1631 例因疑似急性心肌梗死而就诊于急诊科的患者,采用一种新的 hs-cTnI 检测方法进行 cTnI 检测。本研究的目的是确定 1)阴性预测值(NPV)和诊断急性心肌梗死、1 型心肌梗死和 2 型心肌梗死的敏感性;2)使用 hs-cTnI 检测值低于检测限(<1.9ng/L)或高 STEACS 界值(<5ng/L),以及结合正常心电图(ECG),评估 30 天内急性心肌梗死或心脏性死亡的安全性结局。
170 例患者(10.4%)发生急性心肌梗死,其中 68 例(4.2%)为 1 型心肌梗死,102 例(6.3%)为 2 型心肌梗死。hs-cTnI<检测限(27%)时,急性心肌梗死的 NPV 和敏感性分别为 99.6%(95%置信区间 98.9%-100%)和 98.8%(97.2%-100%)。hs-cTnI<5ng/L(50%)时,急性心肌梗死的 NPV 和敏感性分别为 98.9%(98.2%-99.6%)和 94.7%(91.3%-98.1%)。结合正常心电图,1)hs-cTnI<检测限的 NPV 为 99.6%(98.9%-100%),敏感性为 99.4%(98.3%-100%);2)hs-cTnI<5ng/L 的 NPV 为 99.5%(98.8%-100%),敏感性为 98.8%(97.2%-100%)。hs-cTnI<检测限或结合正常心电图,或 hs-cTnI<5ng/L 结合正常心电图的安全性结局的 NPV 和敏感性均非常好。
使用 hs-cTnI 检测值或结合正常心电图,可即刻排除不太可能发生急性心肌梗死且 30 天内发生不良事件风险极低的患者。